# MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Source: https://onco.cc/trials/nct06277154/  
OnCo record `nct06277154` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Doxorubicin, Ifosfamide in vascular tumours and epithelioid sarcoma, run by HRYZ Biotech Co., now recruiting.

## Summary

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06277154 by HRYZ Biotech Co., with 148 participants planned, started 2024-02-21 and due to reach its primary completion in 2026-02. Interventions recorded: MASCT-I, Doxorubicin, Ifosfamide. Conditions listed: Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06277154
- Phase: 2
- Setting: A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
- Sponsor: HRYZ Biotech Co.
- Enrolled: 148

## Sources

- ClinicalTrials.gov NCT06277154: https://clinicaltrials.gov/study/NCT06277154

## Connected records

- cancers: [Epithelioid sarcoma](https://onco.cc/cancers/epithelioid-sarcoma/), [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/), [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/), [Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)](https://onco.cc/cancers/vascular-tumours/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/)

---
JSON: https://onco.cc/api/v1/entities/nct06277154.json